08.07.2023 | Tracker

Product Launch Tracker: eHCPs are delighted with the approval of Talzenna for prostate cancer.

By Alexandra Maria Chatziioannidou

Every month, CREATION.co’s tracking updates bring you the latest insights from the conversation of healthcare professionals (HCPs) across the globe discussing product launches. Discover which new drug approvals HCPs are talking about, what they think about them, and which online sources they are using to inform their opinions and conversations in CREATION.co’s latest tracking update.

Throughout June 2023 we tracked the global conversations of 1,949 eHCPs who posted 2,817 English-language Twitter posts about the launches and approvals of new products.

In June, several product approvals were discussed online by HCPs. They offered their thoughts on the first ever gene therapy treatment for DMD, as well as sharing their enthusiasm about the approval of Talzenna, a new therapy shaping the future of prostate cancer.

During June, the FDA approved Elevidys by Sarepta Therapeutics, the first gene therapy for the treatment of paediatric patients four to five years of age with Duchenne muscular dystrophy (DMD). eHCPs were on the fence regarding this accelerated approval as they discussed some limitations in the trial’s results, and several clinical professionals did not agree with the decision. However, a number of eHCPs were enthusiastic about the approval calling it a “groundbreaking treatment”.

On 20 June, the FDA announced the approval of Pfizer’s Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide), for the treatment of adult patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC). eHCPs were very pleased to see this treatment approved, as they commented on the remarkable results of the clinical trial and labelled it as a significant leap forward in prostate cancer treatment.

On 15 June, the FDA has granted accelerated approval to Genentech’s Columvi (glofitamab-gxbm) as a therapy for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) or large B-cell lymphoma arising from follicular lymphoma. eHCPs called the day a historical one for DLBCL and were rather excited about the treatment. They quoted “great news for patients” and hoped to be approved in other countries soon.

On 20 June, the FDA approved the first anti-inflammatory drug for reducing cardiovascular events among adults who have established atherosclerotic cardiovascular disease (ASCVD) under the name Lodoco (colchicine). AGEPHA Pharma’s drug reduces the risk of cardiac event risk by an additional 31%. There was a small number of eHCPs who were concerned about the possibility of a price increase for generic colchicine. However, overall, eHCPs were quick to recommend the new treatment online, as an effective option, calling the approval “a new era” in residual inflammatory ASCVD risk. 

The three most shared links from HCPs discussing product launches in June were:

Each month, CREATION.co tracks the HCP conversation relating to new product launches.

You can keep up to date with this and a variety of other topics including virtual congress, healthcare changes since the pandemic, product development and therapy area specific insights within the Tracking section of CREATION Knowledge, or sign up to receive our monthly eJournal with all of our latest HCP insights. 

To stay up to date, you can sign up to CREATION.co’s monthly eJournal.


  • Using CREATION Pinpoint® the English-language Twitter conversations of eHCPs globally discussing new pharmaceutical product launches and drug approvals between 1 June and 30 June 2023 were analysed in order to discover which new product launches eHCPs are discussing as well as #WhatHCPsThink.
  • Mentions of drug approvals by the FDA, EMA, NICE, and CHMP were included in the data, as well as mentions of ‘drug approval’ by eHCPs in their Twitter conversations.
  • Between 1 June and 30 June 2023, there were 2,817 eHCP mentions of new pharmaceutical product launches and drug approvals from 1,949 unique eHCP authors from around the world. 

Click here to read the latest Product launch tracker

View all articles >

Meet the Author

Alexandra Maria Chatziioannidou

As a Biological Sciences graduate, Alexandra is passionate about making an impact in the healthcare industry through creating actionable insights and telling stories with data from online healthcare conversations.

Alexandra loves spending quality time with friends and family, both in the UK and back home in Greece, on her holidays. She also enjoys exploring new places!

Suggested next

05.01.2024 | Article

Product Launch Tracker: Hundreds of eHCPs are enthusiastic about the first Sickle Cell Disease gene therapies.

Discover which new drug approvals HCPs are talking about

By Alexandra Maria Chatziioannidou

31.01.2023 | Article

The divided UK eHCP opinions on Medical Cannabis

Many see medical cannabis as an alternative medicine to relieve some patients symptoms

By Mark Sullivan

View all articles >